Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 8, pp 1181–1183 | Cite as

 Antithrombotic therapy and intracranial bleeding in subjects with sporadic brain arteriovenous malformations: preliminary results from a retrospective study

  • Cindy TiseoEmail author
  • Antonio Carolei
IM - COMMENTARY
  • 31 Downloads

Brain arteriovenous malformations (AVMs) are anomalies of the vascular system of the brain, consisting of tangles of dilatated blood vessels, called the nidus, which connect the feeding arteries directly to the venous drainage without any interposed capillary bed. The exact pathogenic mechanism of AVMs formation is yet poorly understood, but it has been hypothesized that both genetic mutations and angiogenic stimulation play roles in their development. The vast majority of AVMs in the general population has a sporadic origin, but some lesions can occur as a part of hereditary syndromes, such as arteriovenous malformation syndrome and hereditary hemorrhagic telangiectasia, that result from mutations of genes involved in angiogenesis and vascular remodeling.

Despite the low estimated incidence (about 1.3 per 100,000 inhabitants per year) [1] and prevalence rates (10–18 per 100,000 persons) [1], and the low proportion of symptomatic patients (12%), AVMs pose a relevant neurological issue...

Notes

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Derdeyn CP, Zipfel GJ, Albuquerque FC, Cooke DL, Feldmann E, Sheehan JP, Torner JC, Council American Heart Association Stroke (2017) Management of Brain Arteriovenous Malformations: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 48(8):e200–e224CrossRefGoogle Scholar
  2. 2.
    Kim H, Al-Shahi Salman R, McCulloch CE, Stapf C, Young WL, Coinvestigators MARS (2014) Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors. Neurology 83:590–597CrossRefGoogle Scholar
  3. 3.
    Gross BA, Du R (2013) Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg 118:437–443CrossRefGoogle Scholar
  4. 4.
    Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ, International ARUBA Investigators (2014) Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 383:614–621CrossRefGoogle Scholar
  5. 5.
    Darsaut TE, Magro E, Gentric JC, Batista AL, Chaalala C, Roberge D, Bojanowski MW, Weill A, Roy D, Raymond J (2015) Treatment of brain AVMs (TOBAS): study protocol for a pragmatic randomized controlled trial. Trials 16:497CrossRefGoogle Scholar
  6. 6.
    Jabbari E, Sethuraman S, Sekaran L (2014) The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation. BMJ Case Rep 15:19.  https://doi.org/10.1136/bcr-2013-201315 CrossRefGoogle Scholar
  7. 7.
    Ricci S, Pistoia F, Carolei A, Sacco S (2015) Restarting oral anticoagulants after intracerebral hemorrhage: cons. Intern Emerg Med 10:5–7CrossRefGoogle Scholar
  8. 8.
    Birocchi S, Podda GM, GrAM (Gruppo di Auto formazione Metodologica) (2017) Oral anticoagulants for stroke prevention in patients with atrial fibrillation and previous intracranial hemorrhage. Intern Emerg Med 12(4):527–529CrossRefGoogle Scholar
  9. 9.
    Sturiale CL, Pignotti F, Giordano M, Porfidia A, Albanese A, Giarretta I, Puca A, Gaetani E, Darrigo S, Truma A, Olivi A, Pola R, Sporadic AVMs-HHT Study Group (2018) Antithrombotic therapy and intracranial bleeding in subjects with sporadic brain arteriovenous malformations: preliminary results from a retrospective study. Intern Emerg Med.  https://doi.org/10.1007/s11739-018-1918-7 CrossRefPubMedGoogle Scholar
  10. 10.
    Langer DJ, Lasner TM, Hurst RW, Flamm ES, Zager EL, King JT Jr (1998) Hypertension, small size, and deep venous drainage are associated with risk of hemorrhagic presentation of cerebral arteriovenous malformations. Neurosurgery 42(3):481–486CrossRefGoogle Scholar
  11. 11.
    Hasan DM, Mahaney KB, Brown RD Jr, Meissner I, Piepgras DG, Huston J, Capuano AW, Torner JC, International Study of Unruptured Intracranial Aneurysms Investigators (2011) Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 42(11):3156–3162CrossRefGoogle Scholar
  12. 12.
    Schneble HM, Soumare A, Hervé D, Bresson D, Guichard JP, Riant F, Tournier-Lasserve E, Tzourio C, Chabriat H, Stapf C (2012) Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations. Stroke 43(12):3196–3199CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  1. 1.Neurology and Stroke Unit, Department of Applied Clinical Sciences and Biotechnology, Avezzano HospitalUniversity of L’AquilaL’AquilaItaly

Personalised recommendations